Madrigal Pharmaceuticals
Stock Forecast, Prediction & Price Target

Madrigal Pharmaceuticals Financial Estimates

Madrigal Pharmaceuticals Revenue Estimates

Madrigal Pharmaceuticals EBITDA Estimates

Madrigal Pharmaceuticals Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$0
 
0%
$0
 
0%
Avg: $364.00M
Low: $211.60M
High: $533.77M
avg. 0%
Avg: $969.73M
Low: $585.13M
High: $1.34B
avg. 166.40%
Avg: $1.83B
Low: $1.10B
High: $2.54B
avg. 89.18%
Avg: $2.74B
Low: $1.65B
High: $3.80B
avg. 49.54%
Net Income
 
% change YoY
$-241.07M
 
N/A
$-299.31M
 
-24.15%
$-373.63M
 
-24.82%
Avg: $-405.25M
Low: $-485.90M
High: $-122.21M
avg. -8.46%
Avg: $97.70M
Low: $-299.56M
High: $542.69M
avg. 124.11%
Avg: $677.42M
Low: $328.15M
High: $1.01B
avg. 593.31%
Avg: $1.17B
Low: $571.09M
High: $1.77B
avg. 74.03%
EBITDA
 
% change YoY
$-242.48M
 
N/A
$-291.38M
 
-20.16%
$-379.96M
 
-30.40%
Avg: $0
Low: $0
High: $0
avg. 100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
EPS
 
% change YoY
-$14.58
 
N/A
-$17.47
 
-19.82%
-$19.99
 
-14.42%
Avg: -$18.14
Low: -$26
High: -$6.54
avg. 9.27%
Avg: $3.96
Low: -$16.03
High: $29.04
avg. 121.83%
Avg: $36.25
Low: $17.56
High: $54.53
avg. 815.60%
Avg: $63.09
Low: $30.56
High: $94.9
avg. 74.03%
Operating Expenses
 
% change YoY
$242.48M
 
N/A
$293.57M
 
21.06%
$380.49M
 
29.60%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%

FAQ

What is Madrigal Pharmaceuticals stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 195.74% in 2025-2028.

We have gathered data from 13 analysts. Their low estimate is -485.90M, average is -405.25M and high is -122.21M.

What is Madrigal Pharmaceuticals stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 76.28% in 2025-2028.

We have gathered data from 12 analysts. Their low revenue estimate is $211.60M, average is $364.00M and high is $533.77M.

What is Madrigal Pharmaceuticals stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 255.18% in 2025-2028.

We have gathered data from 13 analysts. Their low earnings per share estimate is -$26, average is -$18.14 and high is $-6.54.

What is the best performing analyst?

In the last twelve months analysts have been covering Madrigal Pharmaceuticals stock. The most successful analyst is Yasmeen Rahimi.